Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Omecamtiv Mecarbil in Healthy Chinese Subjects Authors: Xuening Li, Hui Li, Hongrong Xu, Fei Yuan, Hanjing Chen, Chao Liu, Mengjie Yang, Jing Li, Lei Sheng Published: 2025 ABSTRACT AbstractBackground and ObjectivesThis phase I study was designed to evaluate the safety, tolerability, and pharmacokinetics of omecamtiv mecarbil with multiple oral doses at 25 mg twice daily, followed by titration to either 37.5 or 50 mg twice daily in healthy Chinese participants.MethodsFifty healthy participants were enrolled and randomly assigned into three groups: Group A (20 subjects) received omecamtiv mecarbil 25 mg in period 1 and either 37.5 mg or 25 mg in period 2; Group B (20 subjects) received omecamtiv mecarbil 25 mg in period 1 and either 50 mg or 25 mg in period 2; and Group C (10 subjects) received a placebo in both periods.ResultsThe pharmacokinetics of omecamtiv mecarbil were well characterized in healthy Chinese participants. Across all subgroups, the mean terminal elimination half-life ranged from 18.3 to 21.3 h. Mean accumulation ratios of area under the curve from time 0 to 12 h ranged from 4.54 to 5.01 in period 1 and 2. The mean maximum observed concentration/plasma concentration before dosing ratios varied between 1.23 and 1.31 on days 8 and 34 across subgroups. No subjects experienced serious adverse events. The most frequently reported adverse events were an increased blood creatine kinase levels (12.5% of subjects in the omecamtiv mecarbil group, 10% in the placebo group), increased blood glucose levels (7.5%, 0), and bradycardia (10%, 0).ConclusionsOmecamtiv mecarbil was well tolerated at the dose levels of 25–50 mg in healthy Chinese participants according to a pharmacokinetic-based titration scheme. Exposure of omecamtiv mecarbil was dose proportional, and no dose-related trends were observed in treatment-emergent adverse events. Key Points Omecamtiv mecarbil was well tolerated at the dose levels of 25–50 mg in healthy Chinese participants.Exposure of omecamtiv mecarbil was dose proportional, and no dose-related trends were observed in treatment-emergent adverse events.Pharmacokinetics of omecamtiv mecarbil in healthy Chinese participants were similar to the results observed in healthy Japanese and Caucasian participants. Introduction Omecamtiv mecarbil is a novel, selective, cardiac myosin activator that has shown promise in treating heart failure with reduced ejection fraction (HFrEF) by stabilizing the actin-bound myosin conformation, leading to an increase in the number of myosin heads that are in the “force-generating” state [1]. In several clinical trials, omecamtiv mecarbil has shown promise in reducing heart failure (HF) events and improving cardiovascular outcomes in patients with HF according to a predefined pharmacokinetic (PK)-based titration scheme [2–5]. The phase II COSMIC-HF trial demonstrated significant improvements in cardiac function and biomarkers under the PK-based titration scheme, including changes in systolic ejection time, stroke volume, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and N-terminal pro B-type natriuretic peptide levels [4]. The phase III GALACTIC-HF trial showed that omecamtiv mecarbil under a PK-based dose titration scheme significantly reduced the risk of cardiovascular death or HF events in patients with HFrEF when added to standard therapy [5]. Despite the promising efficacy observed in the GALACTIC-HF, omecamtiv mecarbil was not approved by the US Food and Drug Administration in 2023. The advisory committee had concerns about the modest treatment effect and questions regarding the overall benefit-risk profile [6]. The pharmacokinetics and pharmacodynamics of omecamtiv mecarbil have been investigated in both healthy participants and patients with HFrEF [7–10]. Omecamtiv mecarbil is well tolerated when administered orally or intravenously, with a mean half-life of approximately 20 h [11]. The use of PK-based dose titration in drug administration is an approach that tailors the dosage of a medication to an individual’s PK profile to achieve optimal therapeutic outcomes. The primary reasons for adopting this strategy include individual variability in drug absorption, distribution, metabolism, and excretion, maximizing efficacy and minimizing toxicity, and personalized medicine treatment [12]. Factors such as food, age, weight, liver and kidney function, concurrent medications, and genetic differences can result in variable degrees of systemic exposure after administration of a standard dose [13]. In previous studies, the effect of food on the PK profiles of omecamtiv mecarbil is minimal, and it can be taken with or without food without a significant impact on its absorption [11, 14]. Additionally, mild or moderate hepatic impairment, renal impairment, or hemodialysis do not significantly affect the PK properties of omecamtiv mecarbil [15, 16]. Coadministration of omecamtiv mecarbil with drugs such as amiodarone, digoxin, omeprazole, and metformin does not result in clinically relevant drug–drug interactions [17–19]. Furthermore, inhibitors of cytochrome P450 3A4 and cytochrome P450 2D6 do not have a clinically significant effect on the pharmacokinetics of omecamtiv mecarbil [20]. However, there is an increased risk of cardiac ischemia when plasma concentrations of omecamtiv mecarbil are more than 1200 ng/mL both in healthy volunteers and patients with HF [7, 8]. Therefore, an individualized PK-based titration regimen was developed to mitigate the risk of excessive exposures (> 1000 ng/mL) to omecamtiv mecarbil, while ensuring adequate concentrations for therapeutic efficacy [21, 22]. In order to be registered and listed in China by the National Medical Products Administration, it was necessary to evaluate the safety and tolerability, and pharmacokinetics of omecamtiv mecarbil in healthy Chinese participants according to a predefined titration scheme. Beyond this regulatory requirement, there was a scientific rationale to confirm the PK profile of the established titration scheme in the Chinese population. As the previous study primarily involved Caucasian and Japanese subjects [9], this bridging study was essential to evaluate potential ethno-specific differences in drug exposure and tolerability. This phase I study was designed to evaluate the safety and pharmacokinetics of omecamtiv mecarbil in healthy Chinese participants under oral administration initially at 25 mg twice daily (BID) followed by PK-based titration to 37.5 or 50 mg BID. Methods Participants All subjects enrolled in this study were healthy Chinese participants aged 20–65 years with a body mass index of 18.0–28.0 kg/m2. Subjects were eligible for participation if they were considered by the investigator to be healthy based on vital signs, a 12-lead electrocardiogram, a physical examination, or laboratory tests. Subjects were excluded if troponin I was above the upper limit of normal, and if they had prior exposure to omecamtiv mecarbil. Subjects were also excluded if they were receiving or received any investigational drug within 30 days, or had used prescription or over-the-counter medications within 14 days or five half-lives, or had consumed grapefruit juice or grapefruit-containing products within 7 days. Study Design The study was conducted in accordance with regulations and guidelines established by the International Council for Harmonisation Good Clinical Practice and National Medical Products Administration. This was a randomized, placebo-controlled, double-blind, phase I study (clinical trial registration number: CTR20170957), consisting of dose escalation in healthy Chinese participants to evaluate the safety, tolerability, and pharmacokinetics of omecamtiv mecarbil lead-in with an initial oral dose of 25 mg, followed by subsequent dose adjustments to either 37.5 or 50 mg, respectively, or remaining unchanged at 25 mg according to a prespecified PK-based titration scheme. This PK-based dose-titration regimen was selected directly from the strategy used in pivotal global trials [4, 5] and the Japanese bridging study [9]. The working hypothesis was that this regimen, using a day 8 plasma concentration before dosing (Cpredose) < 200 ng/mL as the criterion for up-titration, would achieve steady-state plasma concentrations that provide therapeutic efficacy without exceeding the safety threshold of 1000 ng/mL, which is associated with an increased risk of cardiac ischemia [7, 8]. This study consisted of two dosing periods: period 1 (“lead-in”, days 1–8) and period 2 (“up-titration”, days 20–34). A washout period separated these two dosing periods. In period 1, a total of 50 eligible subjects were randomly allocated to receive either an omecamtiv mecarbil modified-release 25-mg tablet BID (Group A, N = 20; Group B, N = 20) or a matching placebo BID (Group C, N = 10) from days 1 to 8 (with BID dosing for 7 days, followed by a morning dose on day 8). In period 2, subjects from Group A and B initiated administration at either a 37.5-mg or 50-mg single dose on day 20 according to their randomization group if the day 8 Cpredose was < 200 ng/mL and then BID from days 27 to 34 (only the morning dose on day 34). Subjects with day 8 Cpredose ≥ 200 ng/mL, or for whom a day 8 PK value was not available in time for dose adjustment, remained unchanged at 25 mg until the end of study participation from days 20 to 34. Prior to study initiation, the study protocol was approval by an Independent Ethics Committee at Zhongshan Hospital, Fudan University (approval number: 2019-019). Analysis of PK Profiles Blood samples for the analysis of omecamtiv mecarbil and its metabolites (M3 and M4) were collected using K3EDTA-anticoagulated tubes on day 1: pre-dose (0 h), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 h post-dose, and day 20: pre-dose (0 h), 0.5, 1, 2, 3, 5, 8, 12, 24, 48, 72, 96, 120, 144, and 168 h post-dose. After 7 days of BID administration, an equivalent blood sampling was implemented following the final BID dose on either day 8 or day 34, with collections at pre-dose (0 h), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, and 96 h post-dose. In order to evaluate the steady-state conditions, pre-dose PK samples were obtained before the morning and evening doses on days 6, 7, 32, and 33. Blood samples (3 mL) for the PK analysis were promptly transferred into the ice bath after collection. With a maximum storage duration of 40 min in ice, blood samples were immediately centrifugated at 2000×g for 10 min (4 °C). The separated plasma was aliquoted into two centrifuge tubes and stored at temperatures below − 70 ℃ until further analysis. Notably, blood samples (4 mL) collected at pre-dose on day 8 and day 34 were split into two aliquots. One aliquot at the sampling timepoint was analyzed using a validated liquid chromatography-tandem mass spectrometry method for a PK assessment, which has been described previously [11], while the other aliquot was analyzed using the QMS® Immunoassay for an exploratory analysis. Concentrations below the lower limit of quantification (1.00 ng/mL for omecamtiv mecarbil and 0.500 ng/mL for M3 and M4) were set to zero prior to the data analysis. Safety Assessment Throughout the course of study, a safety assessment was conducted using vital signs such as pulse rate, blood pressure, respiratory rate, and ear temperature, along with a 12-lead electrocardiogram, weight, physical examination, and clinical laboratory tests including hematology, chemistry, urinalysis, troponin I, and creatine kinase-MB. An adverse event (AE) is defined as any untoward medical occurrence in a subject, regardless of its relationship to these treatments. Adverse events were systematically collected at each study visit through spontaneous reports from participants, non-leading questions, and observations by the investigators. The AE grading scale was used based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Statistical Analysis The PK parameters for omecamtiv mecarbil and its metabolites (M3 and M4) were calculated using non-compartmental methods in Phoenix WinNonlin software Version 6.4 (Certara, Princeton, NJ, USA). Maximum observed concentration (Cmax), time at which Cmax attained (Tmax), and concentration before the oral administration (Cpredose) were obtained directed from the concentration–time data. The area under the curve from time 0 to 12 h (AUC12h) after oral administration on days 1, 8, 20, and 34 was calculated by the linear trapezoidal method for ascending concentrations and the log trapezoidal method for descending concentrations. The terminal half-life (t1/2) was calculated as 0.693/λz, in which the terminal-phase elimination rate constant (λz) was estimated by log-linear regression on the terminal phase of the concentration–time profiles. We also calculated the accumulation ratio of AUC12h (e.g., AUC12h AR = AUC12h, day 8/AUC12h, day 1) and the fluctuation coefficient (Cmax/Cpredose) following multiple doses on day 8 and day 34. Results Participant Disposition and Demographics Out of the 169 healthy Chinese participants screened between 4 September, 2019 and 1 April, 2020, 50 were enrolled. The screen failure rate of 70.4% (119/169) is not uncommon for phase I studies with strict inclusion and exclusion criteria. The primary reasons for screening failures were not meeting eligibility criteria, including blood pressure higher than the upper limit of normal and an abnormal heart rate on an electrocardiogram. Eligible subjects were randomly assigned into one of three groups. Group A (n = 20) received an initial dose of omecamtiv mecarbil 25 mg in period 1, followed by dose adjustments to either 37.5 mg or maintenance at 25 mg in period 2. Group B (n = 20) initially received omecamtiv mecarbil 25 mg in period 1, followed by dose up-titration to either 50 mg or continuation at 25 mg in period 2. Group C (n = 10) received a placebo in both treatment periods. During period 1, one subject in group B discontinued dosing because of the sponsor’s decision, while one subject in Group C discontinued dosing because of an AE of increased bilirubin. A total of 48 subjects completed both dosing periods. In period 2, 12 subjects per group (Group A and B) were uptitrated to receive omecamtiv mecarbil 37.5 mg or 50 mg BID. The other subjects (eight subjects, Group A; seven subjects, Group B) remained to receive omecamtiv mecarbil 25 mg BID during period 2. All demographics and baseline characteristics appeared to be comparable among the groups (Table 1). Table 1Demographics and baseline characteristicsParametersGroup AGroup BOMGroup COM 25 mg BIDOM 37.5 mg BIDTotalOM 25 mg BIDOM 50 mg BIDTotalTotalPlaceboPeriod 2Period 2Period 2Period 2(N = 8)(N = 12)(N = 20)(N = 7)(N = 12)(N = 20)(N = 40)(N = 10)Age, mean (SD), years32.0 (9.7)29.4 (5.7)30.5 (7.4)36.6 (7.8)30.3 (5.7)32.6 (6.9)31.5 (7.1)31.3 (3.1)Sex, n (%) Male7 (87.5)11 (91.7)18 (90.0)6 (85.7)12 (100.0)19 (95.0)37 (92.5)9 (90.0) Female1 (12.5)1 (8.3)2 (10.0)1 (14.3)1 (0.0)1 (5.0)3 (7.5)1 (10.0)Ethnicity, n (%) Hispanic/Latino0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Not Hispanic/Latino8 (100.0)12 (100.0)20 (100.0)7 (100.0)12 (100.0)20 (100.0)40 (100.0)10 (100.0) Weight, mean (SD), kg62.8 (5.44)69.1 (6.67)66.6 (6.85)65.7 (10.03)68.9 (6.99)67.5 (7.95)67.1 (7.34)68.6 (8.13) Height, mean (SD), cm167.4 (4.17)171.5 (6.89)169.9 (6.17)168.6 (6.14)170.6 (9.42)169.8 (8.02)169.8 (8.02)169.7 (6.42) BMI, mean (SD), kg/m222.4 (1.34)23.5 (1.60)23.1 (1.57)23.1 (2.63)23.7 (2.09)23.4 (2.21)23.2 (1.90)23.8 (1.85)BID twice daily, BMI body mass index, N number of subjects, OM omecamtiv mecarbil, SD standard deviation Demographics and baseline characteristics BID twice daily, BMI body mass index, N number of subjects, OM omecamtiv mecarbil, SD standard deviation Safety and Tolerability A total of 20 AEs were reported in this study. Of these, 18 (45.0%) were reported in subjects who received omecamtiv mecarbil, while two (20.0%) were reported in the placebo group (Table 2). There was no serious AE in this study. The AEs most commonly reported across treatment groups (observed in two or more subjects in each group) included elevated blood creatine kinase (CK) levels (5/40 subjects receiving omecamtiv mecarbil, 1/10 subjects receiving placebo), increased blood glucose levels (3/40 subjects receiving omecamtiv mecarbil), and bradycardia (4/40 subjects receiving omecamtiv mecarbil). All reported elevations in blood CK levels were asymptomatic, transient, and assessed as grade 1 in severity except one in grade 3. This single grade 3 AE reported in Group B was an isolated and asymptomatic elevation on day 34 (end of study visit) that returned to the normal range on day 42 (follow-up visit). Other CK elevations were < 2 times the upper limit of normal and considered to be of minimal clinical significance. The four non-serious AEs of isolated bradycardia were also considered by the investigator to be of minimal clinical significance. There were no significant changes from baseline or differences across the omecamtiv mecarbil groups in mean pulse rate or PR interval, indicating these events were asymptomatic and not associated with hemodynamic compromise or conduction abnormalities. One subject in the placebo group (Group C) reported a non-serious grade 2 AE of increased bilirubin, which led to withdrawal from the investigational product. This event was asymptomatic, resolved without any intervention after withdrawal, and was assessed by the investigator as unrelated to the study drug (placebo). Additionally, one subject in Group B did not enter the dosing period 2 because of a decision made by the sponsor in response to an AE of diarrhea. Table 2Adverse events of OM with multiple oral doses at 25 mg BID followed by uptitration to either 37.5 mg or 50 mg BID in healthy Chinese subjectsSystem Organ Class Preferred TermGroup AGroup BOMTotalGroup C25 mg BID37.5 mg BIDTotal25 mg BID50 mg BIDTotalPlacebo(N = 8)(N = 12)(N = 20)(N = 7)(N = 12)(N = 20)(N = 40)(N = 10)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)Investigations1 (12.5)2 (16.7)3 (15.0)2 (28.6)5 (41.7)7 (35.0)10 (25.0)2 (20.0) Blood creatine phosphokinase increased1 (12.5)0 (0.0)1 (5.0)0 (0.0)4 (33.3)4 (20.0)5 (12.5)1 (10.0) Blood glucose increased0 (0.0)1 (8.3)1 (5.0)1 (14.3)1 (8.3)2 (10.0)3 (7.5)0 (0.0) Alanine aminotransferase increased0 (0.0)0 (0.0)0 (0.0)1 (14.3)0 (0.0)1 (5.0)1 (2.5)0 (0.0) Aspartate aminotransferase increased0 (0.0)0 (0.0)0 (0.0)1 (14.3)0 (0.0)1 (5.0)1 (2.5)0 (0.0) Blood creatine phosphokinase MB increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (8.3)1 (5.0)1 (2.5)0 (0.0) Blood creatine phosphokinase MM increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (8.3)1 (5.0)1 (2.5)0 (0.0) Blood triglycerides increased0 (0.0)0 (0.0)0 (0.0)1 (14.3)0 (0.0)1 (5.0)1 (2.5)0 (0.0) Blood bilirubin increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (20.0) Bilirubin conjugated increased0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (10.0)Cardiac disorders2 (25.0)2 (16.7)4 (20.0)0 (0.0)1 (8.3)2 (1.0)6 (15.0)0 (0.0) Bradycardia2 (25.0)1 (8.3)3 (15.0)0 (0.0)1 (8.3)1 (5.0)4 (10.0)0 (0.0) Nodal rhythm0 (0.0)1 (8.3)1 (5.0)0 (0.0)0 (0.0)0 (0.0)1 (2.5)0 (0.0) Palpitations0 (0.0)1 (8.3)1 (5.0)0 (0.0)0 (0.0)0 (0.0)1 (2.5)0 (0.0) Ventricular extrasystoles0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (5.0)1 (2.5)0 (0.0)Gastrointestinal disorders1 (12.5)0 (0.0)1 (5.0)0 (0.0)0 (0.0)1 (5.0)2 (5.0)1 (10.0) Diarrhea0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (5.0)1 (2.5)1 (10.0) Nausea1 (12.5)0 (0.0)1 (5.0)0 (0.0)0 (0.0)0 (0.0)1 (2.5)0 (0.0)BID twice daily, N number of subjects, n number of adverse events, OM omecamtiv mecarbil Adverse events of OM with multiple oral doses at 25 mg BID followed by uptitration to either 37.5 mg or 50 mg BID in healthy Chinese subjects BID twice daily, N number of subjects, n number of adverse events, OM omecamtiv mecarbil Pharmacokinetics The PK parameters for omecamtiv mecarbil and its metabolites (M3 and M4) on day 1 (the first dose) and day 8 (the last BID dose) after the oral doses of omecamtiv mecarbil 25 mg in period 1 are shown in Table 3. The PK parameters for omecamtiv mecarbil and its metabolites (M3 and M4) on day 20 (the first dose) and day 34 (the last BID dose) after the oral doses of omecamtiv mecarbil 25, 37.5, and 50 mg in period 2 are shown in Table 4. Figure 1 illustrates the mean plasma concentration–time profiles (semi-log scale) for omecamtiv mecarbil and its metabolites (M3 and M4) following the final BID dose on day 8 after oral administration of omecamtiv mecarbil 25 mg in period 1. Figure 2 illustrates the mean plasma concentration–time profiles (linear and semi-log scale) for omecamtiv mecarbil on day 20 (the first dose) and day 34 (the last BID dose) after oral administrations of omecamtiv mecarbil 25, 37.5, and 50 mg in period 2. Table 3Summary of OM and its metabolites (M3 and M4) on pharmacokinetic parameters after OM 25 mg BID in period 1Parameters25 mgOMM3M4(N = 40)(N = 40)(N = 40)First dose on day 1 Tmax, h4.0 (1.0–12)6.0 (5.0–12)8.0 (5.0–12)d Cmax, ng/mL58.3 (12.2)3.84 (1.36)1.39 (0.507) AUC12h, ng·h/mL530 (108)a37.5 (15.3)c14.5 (5.09)eLast dose on day 8 Tmax, h2.0 (1.0–8.0)6.0 (1.0–10)6.0 (5.0–10) Cmax, ng/mL233 (52.3)23.9 (6.86)9.15 (2.79) AUC12h, ng·h/mL2400 (576)247 (72.1)98.1 (30.8)e t1/2, h20.1 (2.88)31.0 (3.50)b29.5 (4.32)d Cpredose, ng/mL191 (74.4)19.0 (5.20)7.78 (2.62) Cmax/Cpredose1.23 (0.0755)1.25 (0.0795)1.20 (0.0864) AUC12h AR4.54 (3.01)a6.95 (1.32)c7.24 (1.09)Data presented as mean (standard deviation), except for Tmax, which is presented as median (range)AUC12h area under the curve from time 0 to 12 h following the oral dose on days 1, 8, 20, and 34, AUC12h AR accumulation ratio of AUC12h as calculated by AUC12h, day 8/AUC12h, day 1 or AUC12h, day 34/AUC12h, day 20, BID twice daily, Cmax maximum observed concentration, Cmax/Cpredose fluctuation coefficient as calculated by the of Cmax/Cpredose on day 8 or day 34, Cpredose plasma concentration before the oral dose, h hours, OM omecamtiv mecarbil, Tmax time at which Cmax is attained, t1/2 terminal elimination half-lifeaN = 35bN = 38cN = 18dN = 39eN = 10 Summary of OM and its metabolites (M3 and M4) on pharmacokinetic parameters after OM 25 mg BID in period 1 Data presented as mean (standard deviation), except for Tmax, which is presented as median (range) AUC12h area under the curve from time 0 to 12 h following the oral dose on days 1, 8, 20, and 34, AUC12h AR accumulation ratio of AUC12h as calculated by AUC12h, day 8/AUC12h, day 1 or AUC12h, day 34/AUC12h, day 20, BID twice daily, Cmax maximum observed concentration, Cmax/Cpredose fluctuation coefficient as calculated by the of Cmax/Cpredose on day 8 or day 34, Cpredose plasma concentration before the oral dose, h hours, OM omecamtiv mecarbil, Tmax time at which Cmax is attained, t1/2 terminal elimination half-life aN = 35 bN = 38 cN = 18 dN = 39 eN = 10 Table 4Summary of OM and its metabolites (M3 and M4) on pharmacokinetic parameters after OM 25 mg or 37.5 mg or 50 mg BID in period 2Parameters25 mg37.5 mg50 mgOMM3M4OMM3M4OMM3M4(N = 15)(N = 15)(N = 15)(N = 12)(N = 12)(N = 12)(N = 12)(N = 12)(N = 12)First dose on day 20 Tmax, h3.0 (2.0–12)8.0 (5.0–24)8.0 (5.0–24)3.0 (1.0–12)8.0 (5.0–12)8.0 (5.0–24)3.0 (1.0–12)5.0 (5.0–12)10 (5.0–24) Cmax, ng/mL66.9 (12.8)4.70 (1.43)1.71 (0.499)80.3 (13.2)5.32 (1.63)2.37 (0.989)121 (35.9)7.93 (3.19)2.66 (0.924) AUC12h, ng·h/mL588 (85.1)43.0 (13.7)14.8 (4.76)713 (85.0)48.6 (16.3)20.7 (8.15)1020 (167)70.6 (28.4)23.3 (8.93) t1/2, h20.5 (2.71)38.4 (12.1)b26.5 (0.00)e20.3 (3.89)a34.0 (7.30)c26.4 (5.19)g18.3 (3.73)35.9 (9.17)26.4 (8.77)gLast dose on day 34 Tmax, h2.0 (1.0–5.0)6.0 (5.0–10)5.0 (5.0–8.0)2.0 (0.5–8.0)6.0 (3.0–8.0)5.5 (3.0–8.0)3.5 (0.5–5.0)6.0 (3.0–8.0)5.0 (3.0–8.0) Cmax, ng/mL279 (63.6)27.8 (5.71)10.8 (3.37)329 (32.8)30.3 (7.43)14.1 (3.49)487 (78.0)44.7 (15.0)17.0 (8.21) AUC12h, ng·h/mL2870 (723)295 (63.2)115 (33.8)3340 (365)316 (78.5)150 (39.3)4790 (823)467 (153)183 (87.4) t1/2, h21.3 (3.27)32.0 (4.27)b31.5 (4.03)f19.6 (1.21)31.3 (2.42)28.3 (2.59)19.0 (3.37)31.2 (4.90)d28.1 (5.29)a Cpredose, ng/mL223 (58.1)21.8 (5.39)8.69 (2.73)267 (33.9)23.9 (5.40)11.7 (2.60)373 (63.8)35.0 (11.7)14.2 (6.38) Cmax/Cpredose1.26 (0.066)1.29 (0.109)1.24 (0.0992)1.24 (0.0882)1.27 (0.0904)1.20 (0.104)1.31 (0.0850)1.27 (0.0663)1.20 (0.122) AUC12h AR5.01 (1.58)7.28 (1.67)8.34 (3.09)4.72 (0.583)6.75 (1.14)7.51 (1.26)4.74 (0.813)6.80 (1.36)7.67 (1.86)Data presented as mean (standard deviation), except for Tmax, which is presented as median (range)AUC12h area under the curve from time 0 to 12 h following the oral dose on days 1, 8, 20, and 34, AUC12h AR accumulation ratio of AUC12h as calculated by AUC12h, day 8/AUC12h, day 1 or AUC12h, day 34/AUC12h, day 20, Cmax maximum observed concentration, Cmax/Cpredose fluctuation coefficient as calculated by the of Cmax/Cpredose on day 8 or day 34, h hours, OM omecamtiv mecarbil, Tmax time at which Cmax is attained, Cpredose plasma concentration before the oral dose, t1/2 terminal elimination half-lifeaN = 11bN = 13cN = 9dN = 10eN = 1fN = 14gN = 4 Summary of OM and its metabolites (M3 and M4) on pharmacokinetic parameters after OM 25 mg or 37.5 mg or 50 mg BID in period 2 Data presented as mean (standard deviation), except for Tmax, which is presented as median (range) AUC12h area under the curve from time 0 to 12 h following the oral dose on days 1, 8, 20, and 34, AUC12h AR accumulation ratio of AUC12h as calculated by AUC12h, day 8/AUC12h, day 1 or AUC12h, day 34/AUC12h, day 20, Cmax maximum observed concentration, Cmax/Cpredose fluctuation coefficient as calculated by the of Cmax/Cpredose on day 8 or day 34, h hours, OM omecamtiv mecarbil, Tmax time at which Cmax is attained, Cpredose plasma concentration before the oral dose, t1/2 terminal elimination half-life aN = 11 bN = 13 cN = 9 dN = 10 eN = 1 fN = 14 gN = 4 Mean plasma concentration–time profiles (semi-log scale) for omecamtiv mecarbil and its metabolites (M3 and M4) following the final twice-daily dose on day 8 after oral administration of omecamtiv mecarbil 25 mg in period 1. Data are shown as mean (standard deviation). h hours Mean plasma concentration–time profiles (linear and semi-log scale) for omecamtiv mecarbil on day 20 (the first dose) and day 34 (the last twice-daily dose) after oral administrations of omecamtiv mecarbil 25, 37.5, and 50 mg in period 2 on the linear scale (a and b) and semi-log scale (c and d). Data are shown as mean (standard deviation). h hours The mean Cmax values for omecamtiv mecarbil, M3, and M4 on day 20 (period 2) were consistent with those observed on day 1 (period 1), with ranges of 58.3–66.9 ng/mL, 3.84–4.70 ng/mL, and 1.39–1.71 ng/mL, respectively. Similar results were observed in other PK parameters, such as Tmax and AUC12h. Following the last BID dose of omecamtiv mecarbil 25 mg on day 8 (period 1) and day 34 (period 2), the mean Tmax for omecamtiv mecarbil, M3, and M4 remained consistent in both periods. Unlike Tmax, there was also a mild increase in PK parameters (Cpredose, Cmax, AUC12h, t1/2, AUC12h AR, and Cmax/Cpredose ratios) on day 34. Following the initial administration of omecamtiv mecarbil 25, 37.5, and 50 mg on day 20 (period 2), the mean AUC12h for omecamtiv mecarbil, M3, and M4 ranged from 588 to 1020 ng·h/mL, from 43.0 to 70.6 ng·h/mL, and from 14.8 to 23.3 ng·h/mL, respectively. Following the last BID dose of omecamtiv mecarbil 25, 37.5, and 50 mg, the mean AUC12h AR for omecamtiv mecarbil ranged from 4.54 to 5.01 on day 8 (period 1) and day 34 (period 2). Additionally, the mean Cmax/Cpredose ratios for omecamtiv mecarbil were from 1.23 to 1.31 on day 8 and day 34 across all subgroups. In both period 1 and 2, the mean t1/2 for omecamtiv mecarbil ranged from 18.3 to 21.3 h. The PK parameters (Tmax, t1/2, and Cmax/Cpredose ratios) for M3 and M4 remained consistent following single and multiple doses of omecamtiv mecarbil in both periods. Discussion Previous studies evaluated the pharmacokinetics, pharmacodynamics, and safety of omecamtiv mecarbil in either healthy participants or patients with HFrEF [7–9, 11]. In an ethical study, healthy Japanese and Caucasian subjects were administered initially at 25 mg BID followed by PK-based titration to 37.5 or 50 mg BID [9]. In order to evaluate the clinical outcome of omecamtiv mecarbil for the treatment of HF in China, it was imperative to evaluate the pharmacokinetics and safety of omecamtiv mecarbil in healthy Chinese participants in the same PK-based titration scheme. In this study, the mean Cmax for omecamtiv mecarbil was 487 ± 78.0 ng/mL after the final dose of 50 mg on day 34, suggesting that omecamtiv mecarbil at the up-titration scheme is unlikely to increase the risk of myocardial ischemia. Moreover, the mean Cmax/Cpredose ratios for omecamtiv mecarbil, M3, and M4 ranged from 1.20 and 1.31 after multiple doses of 25, 37.5, and 50 mg, which was consistent with the ratios observed in healthy Japanese subjects [9]. The overall study conclusion based on an analysis by dose group was that no dose-related trends were observed in treatment-emergent AEs. While the incidence of asymptomatic CK elevations was observed to be higher in the omecamtiv mecarbil 50 mg BID subgroup (4 of 12 subjects) compared with the 37.5 mg and 25 mg subgroups (1 of 28 subjects combined), these events were transient, asymptomatic, and resolved. Other common AEs, such as bradycardia, did not show a clear dose relationship (three cases in Group A vs one case in Group B). These findings supported the study’s primary conclusion of good tolerability across the tested 25 mg to 50 mg dose range. In the first-in-human study, omecamtiv mecarbil was shown to increase systolic ejection time in a dose-dependent manner in healthy volunteers [8]. Subsequently, in the dose-ranging phase II trial, omecamtiv mecarbil demonstrated significant improvement in cardiac function in patients with stable HF due to left ventricular systolic dysfunction [7]. Given the positive efficacy results from previous studies, further confirmation of pharmacodynamics in healthy subjects was deemed unnecessary. Therefore, the pharmacodynamics of omecamtiv mecarbil were not evaluated in healthy subjects in this study, nor in healthy subjects of the Japanese ethnical study [9]. This decision was also based on the established dose-dependent increases in systolic ejection time observed in earlier healthy volunteer studies [8]. In period 2, healthy subjects in the ethical study received omecamtiv mecarbil BID from day 20 to day 27 [9], while in this study, healthy subjects received a single dose of omecamtiv mecarbil on day 20, followed by BID dosing from day 27 to day 34. In this study, PK parameters (Cmax, Tmax, and AUC12h,) were comparable on day 1 and day 20. Notably, dose-proportional increases in exposure (Cmax and AUC12h) were observed following single doses of 25, 37.5, and 50 mg of omecamtiv mecarbil, which was consistent with findings from prior studies [8, 9, 14]. Although the mean t1/2 is approximately 20 h [11], the BID dosing regimen was selected because it is the established regimen used with the modified-release formulation in the major phase II (COSMIC-HF) and phase III (GALACTIC-HF) clinical trials [4, 5]. This regimen was designed to maintain plasma concentrations within a narrow therapeutic window and minimize peak-to-trough fluctuations. Our study confirmed this approach, observing a low mean fluctuation ratio (Cmax/Cpredose) of 1.23/1.31 across all subgroups (Tables 3 and 4). Omecamtiv mecarbil is primarily metabolized through decarboxylation to a metabolite (M3), which then undergoes further transformation to form a lactam of M3 (M4) [23]. After both single and multiple doses of omecamtiv mecarbil in this study, the exposure (Cmax and AUC12h) of omecamtiv mecarbil was approximately ten times higher than that of its main metabolites (M3 and M4), which was consistent with the previous finding showing that omecamtiv mecarbil was the most abundant component, with M3 and M4 being its primary metabolites [23]. Considering the similarity of PK parameters to those reported in previous studies, it is reasonable to anticipate that the pharmacodynamics will also exhibit comparability to those observed in other populations. Conclusions Omecamtiv mecarbil was well tolerated at dose levels of 25–50 mg in healthy Chinese participants according to a PK-based titration scheme. Exposure of omecamtiv mecarbil was dose proportional, and no dose-related trends were observed in treatment-emergent AEs. Acknowledgments We are grateful to all participants, investigators, and people who participated in the study. Funding This study was supported by Amgen, Inc. and by grants from the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (grant number: 2018ZX09734-001). Declarations Conflict of Interest Xuening Li, Hui Li, Hongrong Xu , Fei Yuan, Hanjing Chen, Chao Liu, Mengjie Yang, Jing Li, and Lei Sheng have no conflicts of interest that are directly relevant to the content of this article. Ethical Approval This study was conducted in accordance with regulations and guidelines established by the International Council for Harmonisation Good Clinical Practice and the National Medical Products Administration. The study was registered at the Chinese Clinical Trial Registry (Registration no. CTR20170957; date of registration: 3 April, 2019). Prior to study initiation, the study protocol was approval by an Independent Ethics Committee at Zhongshan Hospital, Fudan University (approval number: 2019-019). Consent to Participate All participants provided written informed consent before the study. Consent for Publication Not applicable. Availability of Data and Material All datasets generated in this study are available from the corresponding author upon reasonable request for research purposes. Code Availability Not applicable. Author Contributions LS contributed to the analysis and interpretation of the data and writing of the initial draft of the paper. XL and HL were involved in the drafting process of the paper. HX, FY, HC, CL, MY, and JL performed the clinical trial. All authors have read and approved the final version. Footnotes Xuening Li and Hui Li contributed equally to this work. References